BRPI0923649A2 - polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados. - Google Patents

polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.

Info

Publication number
BRPI0923649A2
BRPI0923649A2 BRPI0923649A BRPI0923649A BRPI0923649A2 BR PI0923649 A2 BRPI0923649 A2 BR PI0923649A2 BR PI0923649 A BRPI0923649 A BR PI0923649A BR PI0923649 A BRPI0923649 A BR PI0923649A BR PI0923649 A2 BRPI0923649 A2 BR PI0923649A2
Authority
BR
Brazil
Prior art keywords
ply
polypeptides
streptococcus pneumoniae
pneumoniae pneumolysin
modified streptococcus
Prior art date
Application number
BRPI0923649A
Other languages
English (en)
Inventor
Eliud Oloo
Jeremy Yethon
Martina Ochs
Raymond Comen
Original Assignee
Netherlands Vaccine Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Vaccine Inst filed Critical Netherlands Vaccine Inst
Publication of BRPI0923649A2 publication Critical patent/BRPI0923649A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0923649A 2008-12-24 2009-12-22 polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados. BRPI0923649A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14080408P 2008-12-24 2008-12-24
PCT/CA2009/001843 WO2010071986A1 (en) 2008-12-24 2009-12-22 Modified steptococcus pneumonia pneumolysin (ply) polypeptides

Publications (1)

Publication Number Publication Date
BRPI0923649A2 true BRPI0923649A2 (pt) 2016-01-19

Family

ID=42286822

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923649A BRPI0923649A2 (pt) 2008-12-24 2009-12-22 polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.

Country Status (11)

Country Link
US (3) US8758766B2 (pt)
EP (1) EP2376526A4 (pt)
KR (1) KR101741426B1 (pt)
CN (2) CN106008679A (pt)
AU (1) AU2009329782B2 (pt)
BR (1) BRPI0923649A2 (pt)
CA (1) CA2748149C (pt)
IL (2) IL213734A (pt)
MX (1) MX2011006922A (pt)
WO (1) WO2010071986A1 (pt)
ZA (1) ZA201104627B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075822A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US9944680B2 (en) 2010-12-03 2018-04-17 Sandfi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EA201391456A1 (ru) * 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
US9474689B2 (en) 2011-10-25 2016-10-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CA2888321A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) * 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
BR112017010696A2 (pt) * 2014-11-21 2017-12-26 Univ Oklahoma mutantes de pneumolisina e métodos de utilização deste mutante
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
KR102076417B1 (ko) * 2018-08-01 2020-02-11 윤현규 측방유동분석법을 이용한 세균성 폐렴균의 검출 방법 및 키트
SG11202102007UA (en) 2018-09-12 2021-03-30 Affinivax Inc Multivalent pneumococcal vaccines
EP3747903A1 (en) * 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN113480622A (zh) * 2021-08-05 2021-10-08 江苏坤力生物制药有限责任公司 一种重组肺炎球菌溶血素制备及纯化的方法
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
ATE132195T1 (de) 1987-03-02 1996-01-15 Whitehead Biomedical Inst Rekombinant-mykobakterielle impfstoffe
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
EP0449856B1 (en) * 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
EP0587775A4 (en) 1991-06-06 1994-11-02 Medimmune Inc INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES.
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US7111252B1 (en) 1999-09-22 2006-09-19 Harris Scott C Enhancing touch and feel on the internet
US6530482B1 (en) 2000-04-26 2003-03-11 Michael D. Wiseman Tandem shale shaker
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
WO2008022302A2 (en) 2006-08-17 2008-02-21 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US8128939B2 (en) 2007-04-13 2012-03-06 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof

Also Published As

Publication number Publication date
KR101741426B1 (ko) 2017-05-30
MX2011006922A (es) 2012-06-12
US8951531B2 (en) 2015-02-10
KR20110128800A (ko) 2011-11-30
US9546199B2 (en) 2017-01-17
CN106008679A (zh) 2016-10-12
AU2009329782B2 (en) 2016-01-28
IL213734A0 (en) 2011-07-31
ZA201104627B (en) 2012-05-25
US20150376242A1 (en) 2015-12-31
EP2376526A4 (en) 2013-02-27
AU2009329782A1 (en) 2011-08-04
US20140341942A1 (en) 2014-11-20
WO2010071986A1 (en) 2010-07-01
US8758766B2 (en) 2014-06-24
EP2376526A1 (en) 2011-10-19
CA2748149C (en) 2018-03-06
CN102712680A (zh) 2012-10-03
CA2748149A1 (en) 2010-07-01
IL229526A0 (en) 2013-12-31
US20110287046A1 (en) 2011-11-24
IL213734A (en) 2017-09-28
CN102712680B (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
BRPI0923649A2 (pt) polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0922391A2 (pt) pneumático.
AP2010005424A0 (en) Assays.
EP2330193A4 (en) IMPROVED ANTIBODY MOLECULE
PL384365A1 (pl) Klej, zwłaszcza do kształtek klinkierowych
EP2059807A4 (en) DIAGNOSIS OF PNEUMOCOCCUS PNEUMONIA
BRPI0923418A2 (pt) pneumático.
BRPI0907925A2 (pt) Ativadores de glicoquinase.
BRPI0912226A2 (pt) Moldagem de chocolate.
BRPI0817746A2 (pt) Fio de extensão de termopar.
BRPI0912762A8 (pt) parte de distribuidor.
ZA201004533B (en) Assay for diagnosing streptococcus pneumoniae
BRPI0923387A2 (pt) pneumático.
BRPI0912761A2 (pt) parte de distribuidor.
HK1142342A1 (en) Cyclic, cystein-free protein
NL1035103A1 (nl) Verbeterd verplaatsingsmeetsysteem.
BRPI0818283A2 (pt) Veículo.
CL2008000325S1 (es) Automovil.
CL2008000916S1 (es) Automovil.
NL2002066A1 (nl) Trailer.
DK2408577T3 (da) Formningsværktøj, især ælteværktøj
CL2008000782S1 (es) Automovil.
ITPO20080016A1 (it) Tricoceutica, prodotto tricoceutico.
GB0718225D0 (en) Streptococcus pneumoniae

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THE KINGDOM OF THE NETHERLANDS (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.